Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) | Journal of Clinical Oncology
Current Oncology | Free Full-Text | Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion,
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC - Journal of Thoracic Oncology
A) Overall survival of sequential therapy for afatinib followed by... | Download Scientific Diagram
View of Osimertinib (Tagrisso) | Canadian Journal of Health Technologies
Efficacy of TAGRISSO® (osimertinib) in Resectable EGFRm NSCLC
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc)
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | SpringerLink
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
EGFR-positive tumors: the issue of optimal therapy across several lines - memoinOncology
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer | Business Wire
Asco 2020 – Tagrisso shows what early targeting can do | Evaluate
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
Osimertinib in Advanced Lung Cancer with EGFR Mutations - NCI
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Clinical trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer
Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study - The Lancet Regional Health – Western
Why is Tagrisso not reimbursable as 1st-line treatment in Korea? < Hospital < Article - KBR
